within Pharmacolibrary.Drugs.B_BloodAndBloodFormingOrgans.B01A_AntithromboticAgents.B01AE06_Bivalirudin;

model Bivalirudin
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 3.966666666666666e-06,
    adminDuration = 600,
    adminMass = 0.75 / 1000000,
    adminCount = 1,
    Vd = 0.0002,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.00017,
    k12 = 2.1e-05,
    k21 = 2.1e-05);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Bivalirudin</td></tr><tr><td>ATC code:</td><td>B01AE06</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>0.75</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>0.2</td><td>L</td></tr>
    <tr><td>clearance:</td><td>3.4</td><td>mL/min/kg</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Bivalirudin is a synthetic 20-amino acid polypeptide direct thrombin inhibitor used as an anticoagulant, mainly in the setting of percutaneous coronary intervention (PCI), and approved for use as an alternative to heparin, particularly in patients with or at risk for heparin-induced thrombocytopenia. It is approved by the FDA and used in current clinical practice.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics in adult patients undergoing percutaneous coronary intervention, both male and female, normal renal and hepatic function.</p><h4>References</h4><ol><li><p>Zhang, DM, et al., &amp; Cui, YM (2012). Population pharmacokinetics and pharmacodynamics of bivalirudin in young healthy Chinese volunteers. <i>Acta pharmacologica Sinica</i> 33(11) 1387–1394. DOI:<a href=\"https://doi.org/10.1038/aps.2012.37\">10.1038/aps.2012.37</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/22659624/\">https://pubmed.ncbi.nlm.nih.gov/22659624</a></p></li><li><p>Zhang, D, et al., &amp; Cui, Y (2011). Pharmacokinetics, pharmacodynamics, tolerability and safety of single doses of bivalirudin in healthy chinese subjects. <i>Biological &amp; pharmaceutical bulletin</i> 34(12) 1841–1848. DOI:<a href=\"https://doi.org/10.1248/bpb.34.1841\">10.1248/bpb.34.1841</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/22130240/\">https://pubmed.ncbi.nlm.nih.gov/22130240</a></p></li><li><p>Scandroglio, AM, et al., &amp; Pappalardo, F (2021). Impact of CytoSorb on kinetics of vancomycin and bivalirudin in critically ill patients. <i>Artificial organs</i> 45(9) 1097–1103. DOI:<a href=\"https://doi.org/10.1111/aor.13952\">10.1111/aor.13952</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33686696/\">https://pubmed.ncbi.nlm.nih.gov/33686696</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.B.B01AE06 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Bivalirudin;
